TMTeri A. Manolio

Teri A. Manolio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Teri A. Manolio has a total of 482 co-authors. Here are the top co-authors by number of shared publications:

  • Dan M. Roden

    Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA

    11 shared publications
  • Eric D. Green

    National Human Genome Research Institute National Institutes of Health Bethesda Maryland USA

    11 shared publications
  • Marc S. Williams

    Department of Genomic Health, Geisinger, Danville, PA 17822, USA

    11 shared publications
  • Rex L. Chisholm

    Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

    11 shared publications
  • Gail P. Jarvik

    Departments of Medicine (Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA 98195, USA

    10 shared publications
  • Geoffrey S. Ginsburg

    All of Us Research Program, National Institutes of Health, Bethesda, MD 20892, USA

    10 shared publications

Latest Publications

  • Genomic medicine year in review: 2025

    by Teri A. Manolio, Alauna Rupert, Jahnavi Narula, Carol J. Bult, Rex L. Chisholm, Geoffrey S. Ginsburg, Gillian W. Hooker, Gail P. Jarvik, George A. Mensah, Dan M. Roden, et al.


  • Open Access

    Advancing the science of genomic learning healthcare systems

    by Teri A. Manolio, Renee Rider, Carol J. Bult, Rex L. Chisholm, Patricia A. Deverka, Geoffrey S. Ginsburg, Eric D. Green, Gail P. Jarvik, George A. Mensah, Jahnavi Narula, et al.

    Introduction: Identifying key characteristics of exemplar genomic learning healthcare systems (gLHS) and knowledge gaps that can be explored by collaboration among them is likely to accelerate the sharing of best practices and generation of evidence that informs the use of genomics in clinical care. Methods: Deliberations of an expert group convened by the National Human Genome Research Institute (NHGRI) supplemented by relevant literature. Results: Recent advances in genomic data standardization, automated clinical decision support, increased interoperability, and improved genomic technologies have enabled the development of several robust gLHS . They remain concentrated in major academic centers, however, and operate largely independently. Sharing their methods and tools would increase access to these innovations and advance the field. Several gLHS have expressed willingness to collaborate in a coalition designed to gather, evaluate, and disseminate best practices and development needs. Such a coalition has recently been formed under the leadership of NHGRI. Conclusion: Increased collaboration, interoperability, and sharing of genomic information and strategies across gLHS can help define, refine, and disseminate best practices. Such cooperation can improve genomic variant curation and interpretation, diagnostic accuracy, evidence generation, and ultimately patient care through seamless integration of research as an integral component of good clinical care.


  • Genomic medicine year in review: 2024

    by Teri A. Manolio, Jahnavi Narula, Alauna Rupert, Carol J. Bult, Rex L. Chisholm, Geoffrey S. Ginsburg, Eric D. Green, Gillian Hooker, Gail P. Jarvik, George A. Mensah, et al.


  • Open Access

    Patterns of pharmacogenetic variation in nine biogeographic groups

    by Sophia Hernandez, Lucia A. Hindorff, Joannella Morales, Erin M. Ramos, Teri A. Manolio

    Frequencies of pharmacogenetic (PGx) variants are known to differ substantially across populations but much of the available PGx literature focuses on one or a few population groups, often defined in nonstandardized ways, or on a specific gene or variant. Guidelines produced by the Clinical Pharmacogenetic Implementation Consortium (CPIC) provide consistent methods of literature extraction, curation, and reporting, including comprehensive curation of allele frequency data across nine defined “biogeographic groups” from the PGx literature. We extracted data from 23 CPIC guidelines encompassing 19 genes to compare the sizes of the populations from each group and allele frequencies of altered function alleles across groups. The European group was the largest in the curated literature for 16 of the 19 genes, while the American and Oceanian groups were the smallest. Nearly 200 alleles were detected in nonreference groups that were not reported in the largest (reference) group. The genes CYP2B6 and CYP2C9 were more likely to have higher frequencies of altered function alleles in nonreference groups compared to the reference group, while the genes CYP4F2, DPYD, SLCO1B1, and UGT1A1 were less likely to have higher frequencies in nonreference groups. PGx allele frequencies and function differ substantially across nine biogeographic groups, all but two of which are underrepresented in available PGx data. Awareness of these differences and increased efforts to characterize the breadth of global PGx variation are needed to ensure that implementation of PGx‐guided drug selection does not further widen existing health disparities among populations currently underrepresented in PGx data.


  • Top Cited Papers
    Open Access

    Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations

    by Niall J. Lennon, Leah C. Kottyan, Christopher Kachulis, Noura S. Abul-Husn, Josh Arias, Gillian Belbin, Jennifer E. Below, Sonja I. Berndt, Wendy K. Chung, James J. Cimino, et al.

    Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can be implemented in the clinic, including reduced predictive performance of PRSs in diverse populations, and the interpretation and communication of genetic results to both providers and patients. To address these challenges, the National Human Genome Research Institute-funded Electronic Medical Records and Genomics (eMERGE) Network has developed a framework and pipeline for return of a PRS-based genome-informed risk assessment to 25,000 diverse adults and children as part of a clinical study. From an initial list of 23 conditions, ten were selected for implementation based on PRS performance, medical actionability and potential clinical utility, including cardiometabolic diseases and cancer. Standardized metrics were considered in the selection process, with additional consideration given to strength of evidence in African and Hispanic populations. We then developed a pipeline for clinical PRS implementation (score transfer to a clinical laboratory, validation and verification of score performance), and used genetic ancestry to calibrate PRS mean and variance, utilizing genetically diverse data from 13,475 participants of the All of Us Research Program cohort to train and test model parameters. Finally, we created a framework for regulatory compliance and developed a PRS clinical report for return to providers and for inclusion in an additional genome-informed risk assessment. The initial experience from eMERGE can inform the approach needed to implement PRS-based testing in diverse clinical settings.


  • Genomic medicine year in review: 2023

    by Teri A. Manolio, Jahnavi Narula, Carol J. Bult, Rex L. Chisholm, Patricia A. Deverka, Geoffrey S. Ginsburg, Eric D. Green, Gillian Hooker, Gail P. Jarvik, George A. Mensah, et al.


  • Survey of the training needs of genetic assistants supports the creation of genetic assistant training programs

    by Renee A. Rider, Luis Cubano, Ebony B. Madden, Robb K. Rowley, Teri A. Manolio

    Despite the increasing numbers of genetic assistants (GAs) in the genomics workforce, their training needs and how to best prepare GAs for their role have not been well defined. We sought to identify the current educational status of GAs, opinions on their training needs, and attitudes about GA training programs (GATPs). Survey links were emailed to NSGC members, 17 state genetic counseling (GC) professional organizations, and genomic medicine researchers. Respondents (n = 411) included GCs (n = 231) and GAs (n = 136). Like other studies, we found that the GA position is filled by a range of education levels and career aspirations. Most respondents supported the creation of GATPs, with 63% endorsing that GATPs would be helpful and half endorsing a short-term (3 months or less) program. Most believed GATPs should focus on general knowledge, with almost all practical skills learned on-the-job. If more GATPs are created, our survey provides evidence that graduates would be hired. Indeed, of those whose work setting required a bachelor's degree, the number of respondents who favored keeping that requirement was similar to the number who favored hiring a GA without a degree if they attended a GATP. However, there were concerns about GATPs. Many (44%) believed creating GATPs could discourage candidates from becoming GAs. We observed that there are two types of GAs: entry-level and bachelor's-level, with the entry-level being those who do not have and are not working to obtain a bachelor's degree and the bachelor's-level being those who do/are. GATPs could focus on the education of entry-level GAs, while gaps in the knowledge base of bachelor's-level GAs could be addressed by augmenting bachelor's curriculum or providing additional training after hire. Further research on the training needs of GAs and hiring practices of institutions will be vital to understanding their training needs and designing and implementing effective GATPs.


  • Top Cited Papers
    Open Access

    eXclusionarY: 10 years later, where are the sex chromosomes in GWASs?

    by Lei Sun, Zhong Wang, Tianyuan Lu, Teri A. Manolio, Andrew D. Paterson


  • Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results

    by Ozan Dikilitas, Alborz Sherafati, Seyedmohammad Saadatagah, Benjamin A. Satterfield, David C. Kochan, Katherine C. Anderson, Wendy K. Chung, Scott J. Hebbring, Zachary M. Salvati, Richard R. Sharp, et al.

    Background: The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network. Methods: Adult participants (n=18 544) at 7 sites were enrolled in a prospective cohort study to assess the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . FH variant prevalence and penetrance (defined as low-density lipoprotein cholesterol >155 mg/dL) were estimated after excluding participants enrolled on the basis of hypercholesterolemia. Multivariable logistic regression was used to estimate the odds of CHD compared to age- and sex-matched controls without FH-associated variants. Process (eg, referral to a specialist or ordering new tests), intermediate (eg, new diagnosis of FH), and clinical (eg, treatment modification) outcomes within 1 year after return of results were ascertained by electronic health record review. Results: The prevalence of FH-associated pathogenic variants was 1 in 188 (69 of 13,019 unselected participants). Penetrance was 87.5%. The presence of an FH variant was associated with CHD (odds ratio, 3.02 [2.00–4.53]) and premature CHD (odds ratio, 3.68 [2.34–5.78]). At least 1 outcome occurred in 92% of participants; 44% received a new diagnosis of FH and 26% had treatment modified following return of results. Conclusions: In a multisite cohort of electronic health record–linked biobanks, monogenic FH was prevalent, penetrant, and associated with presence of CHD. Nearly half of participants with an FH-associated variant received a new diagnosis of FH and a quarter had treatment modified after return of results. These results highlight the potential utility of sequencing electronic health record–linked biobanks to detect FH.